Fundraising Strategies & Negotiating Term Sheets with HSBC
Join us for an engaging panel discussion with HSBC diving into fundraising strategies, specifically focusing on challenges in this current market. This conversation will also cover strategies for negotiating term sheets, giving you tools to tackle these negotiations in competitive processes.
This panel will feature Lindy Fishburne, Managing Partner at Breakout Ventures, Karl Handelsman, Founder and Managing Partner of Codon Capital, and Jonathan Norris, Managing Director at HSBC Innovation. Jesse Essaff, Director at HSBC Innovation Banking, will moderate the discussion.
Register for the Livestream
About the Speakers
Lindy Fishburne, Breakout Ventures
Lindy Fishburne is Managing Partner of Breakout Ventures and founded Breakout Labs at the Thiel Foundation. She’s been investing at the intersection of technology, biology and chemistry for 14 years backing some of the most important companies emerging from this space including, Twelve, Cytovale and A-Alpha Bio.
Her hands-on experience includes leading two tech companies through rapid growth and exit. In 2010, she created Breakout Labs, a novel fund model that re-defined how early stage, science-driven companies launch. In 2016, she built Breakout Ventures to invest in singular founding teams leveraging science and technology to access huge opportunities in human health and sustainability. Lindy attended Duke University and holds an MBA from University of Texas at Austin.
Karl Handelsman, Codon Capital
Karl D. Handelsman is Founder and Managing Partner of Codon Capital, and a key contributor and builder in the US biotech innovation ecosystem. Through his network and leadership, he drives Codon Capital to intensely focus on the best biotech targets for investments. The key criteria are the team, the technology, and the investment syndicate. Karl is looking for what he calls “an unfair technology advantage, a team uniquely qualified around that technology opportunity, and multiple routes to success.” Without knowing the technology and the team, he notes, the what if should look “impossible” to the outside world.
Karl’s disciplined approach includes coaching at various incubators and teaching healthcare entrepreneurs, e.g., NSF I-Corps Biotech at the National Institutes of Health, National Cancer Institute, Stanford, UCSF, and Imperial College London. He was a personal sponsor of SynBioBeta 1.0, and consulting advisor for Stanford SPARK, University of California Catalyst program, and the California Life Sciences Institute FAST program. He is a member of Life Science Angels. Karl has developed this process to build a better VC, and to support better entrepreneurship in biotech.
Jonathan Norris, HSBC
Jonathan Norris is Managing Director at HSBC Innovation. He previously was a managing director for business development in SVB’s Healthcare practice where oversaw business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than nineteen years of banking experience working with healthcare companies and venture capital firms. Norris earned a bachelor’s degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
Jesse Essaff, HSBC
Jesse Essaff is Director at HSBC Innovation Banking Life Science & Healthcare practice. He previously worked at J.P. Morgan where he was one of the leaders of the firm’s biopharma, diagnostic and tools corporate banking group in the Bay Area. Jesse has more than 12 years of experience working with founders, management teams and investors in the healthcare ecosystem. Jesse earned a bachelor’s degree in business administration from University of San Francisco.
